期刊
EXPERT REVIEW OF ANTICANCER THERAPY
卷 21, 期 6, 页码 583-590出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14737140.2021.1882856
关键词
Pembrolizumab; nivolumab; melanoma; adjuvant; resection
类别
资金
- NIH/NCI [F32 CA254070-01, K23 CA204726]
- James C. Bradford Jr. melanoma fund
Anti-PD-1 therapy with pembrolizumab or nivolumab has become the standard of care for resected stage III or IV melanoma patients, regardless of BRAF mutation status.
Introduction: Regional or distant metastases from melanoma may be surgically resected but remain at high-risk of recurrence. Over the last few years, several treatments have been approved to mitigate this risk. These include anti-PD-1 agents, specifically pembrolizumab and nivolumab. Areas covered: Herein, we will discuss the landscape of pembrolizumab safety and efficacy used in the adjuvant setting for high-risk, resected melanoma. We place this in context with other available adjuvant therapies, and discuss subgroup analyses. Expert opinion: Anti-PD-1 therapy with either pembrolizumab or nivolumab has become a standard of care for patients with resected stage III or IV melanoma. In our practice, we generally offer these agents (which have comparable safety and efficacy profiles) to patients with resected stage IIIb-IV melanoma regardless of BRAF mutation status.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据